Evolution of SARS-CoV-2 immune responses in nursing home residents following full dose of the Comirnaty® COVID-19 vaccine

Participants and study design

Out of 53 nursing home residents enrolled in a previous study [2] with data on B and T cell immunity at a median of 17.5 days (range, 14−35 days) after second vaccine dose (baseline sample), 46 (44 females; median age, 89 years; range, 60−100; Supplementary Table 1) were reassessed (follow-up sample) at a median of 195 days (range, 179−195 days). The remaining 7 patients either died (n=4; in no case attributable to COVID-19) or lacked the follow-up specimen (n=3). Blood specimens were collected in sodium heparin tubes (Beckton Dickinson, U.K. Ltd., UK). Informed consent was obtained from participants. The study was approved by the Hospital Clínico Universitario INCLIVA Research Ethics Committee (February, 2021).

Immunological assays

Total antibodies (IgG and IgM) against SARS-CoV-2-S protein receptor binding domain (RBD) and the nucleoprotein (N) were measured by Roche Elecsys® electrochemiluminescence sandwich immunoassays (Roche Diagnostics, Pleasanton, CA, USA). Cryopreserved plasma (−20 ºC) specimens were thawed and assayed in singlets within 15 days after collection. Plasma specimens were diluted (1/10) for antibody quantitation when appropriate. SARS□CoV□2□S-reactive IFNγ□producing□CD8⁺ and CD4⁺ T cells were enumerated in whole blood by flow cytometry for ICS (BD Fastimmune, BD□Beckton Dickinson and Company□Biosciences, San Jose, CA) as previously described [2].

Statistical methods

Differences between medians were compared using the Mann–Whitney U-test or Wilcoxon test for unpaired and paired data, when appropriate. The Spearman rank test was used for correlation analyses between continuous variables. Two-sided exact P-values were reported. A P-value <0.05 was considered statistically significant. The analyses were performed using SPSS version 20.0 (SPSS, Chicago, IL, USA).

SARS-CoV-2 infectious status of participants

Of the 46 residents, 10 (21.7%) had evidence of SARS-CoV-2 infection at baseline, as determined by both RT-PCR on nasopharyngeal specimens and detection of N-specific antibodies. No additional residents developed N-specific antibodies between sampling times.

SARS-CoV-2-S-specific antibodies

Data on SARS-CoV-2-RBD antibody levels were available for 45 participants. All 43 residents who tested positive at baseline also displayed detectable responses at follow-up, although overall, antibody levels were found to decrease significantly, by a median of 4.8 fold (range, 1.1−39) [median of 2,249 IU/ml at baseline vs. median 307 IU/ml at follow-up, P<0.001 (Figure 1A)]. One of the two remaining residents developed SARS-CoV-2-S-specific antibodies (8 IU/ml) between sampling times. Antibodies waning was documented more frequently (P<0.001) in SARS-CoV-2 naïve (29/35) than in recovered (1/10) residents (Figure 1B).

• Download figure
• Open in new tab

Figure 1.

(A) SARS-CoV-2-S (RBD) plasma antibody (IgG and IgM) levels as measured by Roche Elecsys® Anti-SARS-CoV-2-S immunoassay in nursing home residents with (recovered) or without (naïve) documented prior SARS-CoV-2 infection at baseline (median, 17.5 days) and follow-up (median, 195 days) after complete Comirnaty® COVID-19 vaccination. The limit of detection of the assay is 0.4 IU/ml and its quantification range is between 0.8 and 250 IU/ml. Plasma specimens were further diluted (1/10) for antibody quantitation when appropriate. The assay is calibrated with the first WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody [12]. Bars represent median levels. (B) Individual kinetics of SARS-CoV-2-S (RBD) plasma antibodies in recovered and naïve nursing home residents. P-values for comparisons are shown (ns; not significant).

SARS-CoV-2-S-specific T cells

Data on T cell responses were available for 46 participants. Overall, detectable SARS-CoV-2-S IFN-γ T cells (either CD8⁺, CD4⁺ or both) were documented in 82.6 % (38/46) and 73.9% (34/46) of residents at baseline and follow-up, respectively (P=0.01). The corresponding figures for SARS-CoV-2-S IFN-γ CD8⁺ T cells were 72% (33/46) and 52.1% (24/46). As shown in Figure 2A, 8 of 13 residents testing negative at baseline later acquired detectable responses, albeit at low frequencies (median, 0.08%; range, 0.01−0.21%), whereas SARS-CoV-2-S IFN-γ CD8⁺ T cells were no longer detectable at follow-up in 16 out of 33 residents who tested positive at baseline. SARS-CoV-2-S IFN-γ CD4⁺ T cells were detected in 26% (12/46) and 65.2% (30/46) of residents at baseline and follow-up, respectively. Nineteen participants developed CD4⁺ T cell responses between testing time points (median, 0.1%; range, 0.03-1.14%), whereas one out of 12 with detectable responses at baseline had lost this at follow-up (Figure 2B). The likelihood of having detectable SARS-CoV-2 IFN-γ CD8⁺ and CD4⁺ T at follow-up was higher (P=0.03 and P=0.5) in SARS-CoV-2 recovered (8/10 and 7/10, respectively) than in naïve residents (9/36 and 25/36, respectively). For those with detectable responses at both time points, overall, SARS-CoV-2-S IFN-γ CD8⁺ T cell frequencies decreased significantly (P=0.001) over time whereas the opposite (P=0.01) was seen for CD4⁺ T cells (Figure 2C). Interestingly, the resident lacking anti-RBD antibodies at follow-up had detectable SARS-CoV-2-S CD4⁺ T cell responses.

• Download figure
• Open in new tab

Figure 2.

SARS-CoV-2-S-reactive IFN-γ-producing T cell levels in SARS-CoV-2 naïve and or recovered nursing home residents measured at baseline (median, 17.5 days) and follow-up (median, 195 days) after complete Comirnaty® COVID-19 vaccination. Briefly, heparinized whole blood (0.5□ml) was simultaneously stimulated for 6□h with two sets of 15□mer overlapping peptides (11□mer overlap) encompassing the SARS□CoV□2 Spike (S) glycoprotein (S1, 158 peptides and S2, 157 peptides) at a concentration of 1□μg/ml per peptide, in the presence of 1□μg/ml of costimulatory monoclonal antibodies (mAbs) to CD28 and CD49d. Peptide mixes were obtained from JPT peptide Technologies GmbH (Berlin, Germany). Samples mock-stimulated with phosphate□buffered saline (PBS)/dimethyl sulfoxide and costimulatory antibodies were run in parallel. Brefeldin A (10□μg/ml) was added for the last 4□h of incubation. Blood was then lysed (BD FACS lysing solution) and frozen at −80°C until tested. On the day of testing, stimulated blood was thawed at 37°C, washed, permeabilized (BD permeabilizing solution) and stained with a combination of labeled mAbs (anti□IFNγ□FITC, anti□CD4□PE, anti□CD8□PerCP□Cy5.5, and anti□CD3□APC) for 1□h at room temperature. Appropriate positive (phytohemagglutinin) and isotype controls were used. Cells were then washed, resuspended in 200□μL of 1% paraformaldehyde in PBS, and analyzed within 2□h on an FACSCanto flow cytometer using DIVA v8 software (BD Biosciences Immunocytometry Systems, San Jose, CA). CD3⁺/CD8⁺ or CD3⁺/CD4⁺ events were gated and then analyzed for IFN□γ production. All data were corrected for background IFN-γ production (FITC-labelled isotype control antibody) and expressed as a percentage of total CD8⁺ or CD4⁺ T cells. (A) Individual kinetics for SARS-CoV-2-S-reactive IFN-γ CD8⁺ T cells. (B) Individual kinetics for SARS-CoV-2-S-reactive IFN-γ CD4⁺ T cells. (C) Frequencies of SARS-CoV-2-S-reactive IFN-γ CD8⁺ and CD4+ T cells in nursing home residents with detectable responses at both baseline and follow-up. T cells. P-values for comparisons are shown (ns; not significant).

Supplementary Table 2 shows the combined results for all immunological parameters. No correlation was found between anti-RBD antibody levels and SARS-CoV-2-S IFN-γ CD4⁺ (Rho=-0.015; P=0.94) and CD8⁺ (Rho:-0.18; P=0.87) T cells.